Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit

\[(Week 12 apoAI minus baseline apoAI)/baseline apoAI\] x 100

Time frame: Baseline to 12 weeks (Final Visit)

Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit

\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\] x 100

Time frame: Baseline to 12 weeks (final visit)

Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit

\[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII\] x 100

Time frame: Baseline to 12 weeks (Final Visit)

Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit

\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\] x 100

Time frame: Baseline to 12 weeks (Final Visit)

Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit

\[(Week 12 apoB minus baseline apoB)/baseline apoB\] x 100

Time frame: Baseline to 12 weeks (Final Visit)

Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit

\[(Week 12 hsCRP minus baseline hsCRP)/baseline hSCRP\] x 100

Time frame: Baseline to 12 weeks (Final Visit)